Drug · Other

Carfilzomib

CI-DRUG-00000143Explore in graph →NCIt C52196 CHEMBL451887 CIViC Approved

Regulatory

Approvals (14)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

openfdaRegulatory10 approval records · authority, jurisdiction and indication text as published.

Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
US FDA	—	Efficacy supplement 2025-05-22 (see label)	approved	May 22, 2025	openfda
US FDA	—	Efficacy supplement 2022-06-30 (see label)	approved	Jun 30, 2022	openfda
US FDA	—	Efficacy supplement 2021-11-30 (see label)	approved	Nov 30, 2021	openfda
US FDA	—	Efficacy supplement 2020-08-20 (see label)	approved	Aug 20, 2020	openfda
US

Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.

Data updated 19 hours agoSource updated unknown

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Approved	Phase 4	73	25	28	200	14	CA, EU, US	Jul 20, 2012	2005-09
Non-Hodgkin Lymphoma	Approved	Phase 4	67	20	26	173	2	EU, US	Jul 20, 2012	2005-09
Multiple Myeloma	Approved	Phase 4	66	20	26	157	2	EU, US	Jul 20, 2012	2005-09
Leukemia	Phase2	Phase 2	1	1	0	10	0	—

Curated evidence

Clinical evidence (1)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
PSMD4 Overexpression1
Carfilzomib	Malignant Colorectal Neoplasm

Clinical trials

Trials with this intervention (208)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 151–200 of 208 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02187133	Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma	completed	Phase 1	10	University of California, San FranciscoOTHER	1	Apr 23, 2021	clinicaltrials
NCT02545907	A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis(CATALYST)

Molecule

Record

Kind: Other
Mechanism: 26S proteasome inhibitor
Targets: 38 genes
UNII: 72X6E3J5AR
Aliases: (2S)-N-((1S)-1-Benzyl-2-(((1S)-3-methyl-1-(((2R)-2-methyloxiran-2-yl)carbonyl)butyl)amino)-2-oxoethyl)-4-methyl-2-(((2S)-2-((morpholin-4-ylacetyl)amino)-4-phenylbutanoyl)amino)pentanamide, Carfilnat, Carfilzomib, CFZ, Kyprolis, KYPROLIS, NSC-758252, PR 171, PR-171, PR171

Data updated 22 hours agoSource updated unknown

Identifiers

Codes (9)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

System	Code	Label
ATC (WHO)	L01XG02	CARFILZOMIB
ATC (WHO)	L01XX45	Antineoplastic agents
DIN (Health Canada)